Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes signals by inducing autophagy. Evogliptin can be used to study type 2 diabetes, chronic liver inflammation, osteoporosis and renal impairment.
Molecular Weight:
401.42
CAS Number:
[1222102-29-5]
Formula:
C19H26F3N3O3
Target:
Proteasome|||Autophagy|||Others
T61949
* VAT and and shipping costs not included. Errors and price changes excepted
